Journal of Clinical Research in Pain and Anaesthesia
ISSN: 2689-6141

Academic Strive
Researcher's perception is our reality

Research Article *Volume 6 Issue 1*

Recent Advances in Pain Management: A Special Focus on Spinal Cord Stimulation

Bali J[1]* and Bali N[2]

[1]Department of Ophthalmology, Hindu Rao Hospital, India
[2]Birla Institute of Technology and Science, India

***Corresponding author:** Jatinder Bali, Department of Ophthalmology, NBEMS Course Coordinator, Hindu Rao Hospital, Municipal Corporation of Delhi, Delhi-110007, Chairman, DOS Subcommittee on Information Technology, Practice Automation and Clinical Information Systems Subcommittee, Delhi Ophthalmology Society, India, Tel: 91 9868041025; Email: drjatinderbali@gmail.com

Received Date: November 25, 2024; **Published Date:** January 16, 2025

Abstract

Background: Chronic pain remains one of the most prevalent and debilitating conditions globally, severely impacting quality of life and productivity. Recent advances in pain management, particularly neuromodulation, have introduced innovative solutions for addressing both acute and chronic pain. Among these, spinal cord stimulation (SCS) stands out as a transformative modality, offering effective relief through novel technologies and expanding clinical applications.

Aims: This review highlights recent advances in pain management with a special focus on spinal cord stimulation. It explores technological innovations, expanded indications and clinical outcomes, emphasizing its role a promising modality for chronic pain management.

Methods: The review examines innovations in neuromodulation, such as SCS waveforms, device miniaturization, and closed-loop systems. Advances in related modalities, such as dorsal root ganglion stimulation (DRGS), peripheral nerve stimulation (PNS), and sacroiliac (SI) joint fusion, are also discussed. Clinical studies on efficacy, patient satisfaction, and cost-effectiveness are analyzed to contextualize SCS within broader pain management strategies.

Results: Recent advancements in SCS technology, including high-frequency stimulation (HF10), burst therapy and closed-loop systems have revolutionized chronic pain management by improving efficacy, comfort, and personalization. Expanded indications for SCS now encompass conditions such as persistent spine pain syndrome (PSPS), complex regional pain syndrome (CRPS), and painful diabetic neuropathy (PDN). Related modalities like DRGS and PNS provide targeted solutions for specific pain syndromes while innovations in telemedicine and biotechnology are enhancing accessibility. Despite these breakthroughs, challenges such as high costs, limited accessibility, and device-specific complications remain.

Conclusions: Spinal cord stimulation is a promising modality in recent pain management advancements offering tailored and effective solutions for diverse pain conditions. Complemented by other neuromodulation and surgical innovations, SCS has significantly improved patient outcomes and quality of life. While challenges persist, ongoing technological and clinical advancements ensure a bright future for personalized pain management. Addressing barriers to accessibility and cost will be key to maximizing the impact of these innovations. This review article aims to bridge this gap in knowledge.

Bali J and Bali N. Recent Advances in Pain Management: A Special Focus on Spinal Cord Stimulation. J Clin Res Pain Anaesthesia 2025, 6(1): 180050.

Keywords: Spinal Cord Stimulation; Neuromodulation; Chronic Pain; High-Frequency Stimulation; Burst Therapy; Pain Management Technology; Personalised Therapy

Abbreviations

SCS: Spinal Cord Stimulation; DRGS: Dorsal Root Ganglion Stimulation; PNS: Peripheral Nerve Stimulation; SI: Sacroiliac; PSPS: Persistent Spine Pain Syndrome; CRPS: Complex Regional Pain Syndrome; PDN: Painful Diabetic Neuropathy; PSP: Pulsed Stimulation Patterns; DTM: Differential Target Multiplex; ECAP: Evoked Compound Action Potential; FBSS: Failed Back Surgery Syndrome; LTP: Long-Term Potentiation; CGRP: Calcitonin Gene-Related Peptide; GABA: Gamma-Aminobutyric Acid; MGLUR: Metabotropic Glutamate Receptor; NK1R: Neurokinin-1 Receptor; BDNF: Brain-Derived Neurotrophic Factor.

Introduction

Chronic pain is one of the most prevalent and debilitating health conditions worldwide, affecting millions and reducing quality of life significantly. Modern pain management has evolved to offer sophisticated, personalized treatment options [1]. Recent advancements in technology, pharmaceuticals, and alternative therapies provide innovative solutions for managing acute and chronic pain.

Neuromodulation: Revolutionizing Pain Therapy

Neuromodulation, particularly Spinal Cord Stimulation (SCS), has made remarkable strides in recent years. It uses electrical impulses to modulate nerve activity and manage pain.Spinal cord stimulation represents a remarkable advancement in chronic pain management [2-4].

Dorsal Root Ganglion Stimulation (DRGS)

Approved in recent years for conditions like CRPS, DRGS focuses on specific nerve clusters to deliver precise pain relief. Its benefits include:

- Targeting smaller, localized areas of pain.
- Effective management of post-surgical pain, phantom limb syndrome, and chronic back pain.

The minimally invasive implantation of DRGS has enhanced patient outcomes while reducing opioid dependence. Studies show a continuous improvement in quality of life over time, making it a promising alternative to traditional therapies [5].

Peripheral Nerve Stimulation (PNS)

PNS targets specific nerves in the peripheral nervous system, using electrical currents to block pain signals. It is commonly used for:

- Facial and chest pain.
- Phantom limb pain and post-traumatic nerve injuries.
- Chronic headaches and pelvic pain.

Advancements in PNS include percutaneous (minimally invasive) lead placements and temporary devices like the SPRINT system, which can be removed after 60 days while maintaining pain relief [6,7].

Sacroiliac (SI) Joint Fusion for Back Pain

SI joint dysfunction is an underdiagnosed cause of chronic back pain. Innovations in SI joint fusion techniques offer effective alternatives to long-term opioid use. Modern devices like the iFuse Implant System provide:

- Minimally invasive procedures with reduced recovery times.
- Long-term pain relief and increased joint stability.

Studies have reported significant improvements in patient-reported outcomes, reduced opioid use, and fewer complications compared to older surgical methods [8,9].

Telemedicine and Virtual Health Technologies

The COVID-19 pandemic accelerated the adoption of telehealth for pain management. Innovations in this area include:

- Mobile apps for pain tracking and symptom monitoring.
- Virtual reality for managing phantom limb pain.
- Neurofeedback therapy using EEG headsets for remote treatment.

These tools improve accessibility, especially in rural areas, and provide cost-effective solutions for managing chronic pain [10].

Advances in Biotechnology and Pharmaceuticals

Biotechnology has introduced groundbreaking therapies for pain, including:

- Gold Nanorods: Conjugated with RNA for targeted pain relief in preclinical trials.
- Magnetofection: A technique using magnetic nanoparticles for precise drug delivery.
- Transdermal Devices: Offering controlled, long-term release of analgesics.

These innovations aim to reduce side effects and provide tailored treatments for chronic pain patients [11].

Challenges in Pain Management

Despite these advances, significant challenges remain:

- High costs of new technologies.
- Limited access for underserved populations.
- The need for robust clinical trials to validate emerging therapies [9,11,12].

Spinal Cord Stimulation (SCS) for Pain Management

Spinal Cord Stimulation (SCS) is a cutting-edge neuromodulation therapy designed to treat chronic pain. It has revolutionized pain management by providing relief without the heavy reliance on opioids or invasive surgeries. SCS works by altering pain signals before they reach the brain, offering a life-changing alternative for patients with intractable pain [6,13,14].

What is Spinal Cord Stimulation?

Spinal cord stimulation (SCS) has undergone significant advancements becoming a cornerstone for managing chronic pain. Technological improvements, new indications and better surgical techniques have enhanced its safety, efficacy, and patient satisfaction.

SCS involves the implantation of a small device that delivers low-voltage electrical currents to the spinal cord. The electrical impulses disrupt pain signals traveling through the nerves, replacing them with a mild tingling sensation or, in some cases, no sensation at all (depending on the type of stimulation).

The therapy is particularly effective for conditions like:

- Persistent spinal pain (failed back surgery syndrome).
- Complex Regional Pain Syndrome (CRPS).
- Diabetic neuropathy.
- Chronic back and leg pain [6,13-16].

Mechanism of Action

Pain signals travel from the site of injury to the brain through the spinal cord. SCS modulates these signals in the dorsal horn of the spinal cord, where they are processed before reaching the brain. By delivering electrical currents, the therapy reduces the perception of pain by:

Inhibiting Pain Pathways: The electrical impulses interfere with the transmission of nociceptive (pain-causing) signals.

Stimulating Aβ Fibers: These fibers, responsible for touch and pressure, are activated to create a pleasant tingling sensation (paresthesia) that overrides pain [6,15-17].

Types of Spinal Cord Stimulation

Modern SCS systems offer various types of stimulation to cater to different patient needs:

Traditional Tonic Stimulation:

- Provides constant low-frequency electrical impulses.
- Replaces pain with a tingling sensation (paresthesia).
- Effective but may be less desirable for patients sensitive to the tingling.

High-Frequency Stimulation (HF10):

- Delivers high-frequency pulses (10,000 Hz) without causing paresthesia.
- Particularly effective for back and leg pain.
- FDA-approved and shown to provide long-term pain relief.

Burst Stimulation:

- Mimics natural brain wave patterns.
- Reduces pain without constant tingling.
- Effective for both physical and emotional components of pain.

Closed-Loop Systems:

- Monitors spinal cord activity in real time.
- Adjusts stimulation automatically based on patient movements and posture.
- Provides consistent relief without patient intervention [6,15-18].

Currently Available SCS Devices

Several companies manufacture devices for spinal cord stimulation like Abbott (Prodigy system) , Boston Scientific (Wave Writer Precision Montage Precision Novi systems), Medtronic ,Nevro , Nalu and Saluda . MRI compatibility varies across devices:

- Fully MRI-Compatible Devices: Precision Montage.
- Conditional MRI Compatibility: For head and extremities (e.g., Prodigy System).
- Head-Only Compatibility: WaveWriter System.
- Non-Compatible Devices: Precision Novi.

This variability in MRI compatibility impacts device choice, especially for patients requiring frequent imaging [1,17].

Patient Selection for Spinal Cord Stimulation

A broad consensus has emerged on candidates who are fit for management of chronic pain conditions using the modality of spinal cord stimulation. However there is still a large grey area and a lot of work is still being done on the subject and this list should be taken as an indicative list only.

Inclusion Criteria for Spinal Cord Stimulation

- Adults aged 18 years or older.
- Chronic pain lasting at least 6 months.
- Primary indications include:

1. Chronic low back or leg pain.
2. Complex regional pain syndrome (CRPS).
3. Neuropathic or ischemic pain syndromes.

- Pain rated moderate to severe (VAS ≥ 5) with significant impact on daily life and quality of life.
- Inadequate response to medications or minimally invasive treatments, or intolerable side effects.
- No anticipated benefit from surgical interventions.

Exclusion Criteria for Spinal Cord Stimulation

- Refusal or inability to manage the implanted device.
- Absolute contraindications such as poor surgical fitness, pregnancy, spinal infection, or coagulation disorders.
- Uncontrolled psychological or psychiatric disorders.
- Active alcohol or drug misuse.
- Generalized widespread pain [19].

Procedure for Spinal Cord Stimulation

Spinal cord stimulators consist of electrodes placed in the epidural space and a generator implanted under the skin, typically near the buttocks or abdomen. Patients use a remote control to deliver electrical impulses when experiencing pain. Traditional devices replace pain with a mild tingling sensation (paresthesia). Advanced devices offer "sub-perception" stimulation, eliminating any detectable sensation. Placement is performed by interventional pain specialists using X-ray or ultrasound guidance.

Phases of Procedure

Trial Phase:

- Before permanent implantation, patients undergo a trial period lasting 5–7 days.
- Temporary electrodes are placed on the epidural space via a small incision.
- The patient evaluates the effectiveness of SCS in reducing pain. (Figure 1 & 2)



Figure 1: Patient evaluates the effectiveness of SCS in reducing pain.

Figure 2: Evaluating effectiveness of SCS in reducing pain.

Permanent Implantation: If the trial is successful, a permanent device is implanted. Components include:

- Electrodes: Placed in the epidural space near the spinal cord.
- Pulse Generator: Implanted under the skin, usually in the lower back or abdomen.
- Remote Control: Allows the patient to adjust stimulation settings (Figures 3 & 4).

Figure 3: Permanent Generator.



Figure 4: Remote Programmable.

Post-Procedure Care:

- Regular follow-ups to ensure optimal settings.
- Battery replacements (for non-rechargeable devices) every 5–10 years.
- Minimal recovery time, allowing patients to resume daily activities quickly [17].

Benefits of Spinal Cord Stimulation

Effective Pain Relief:

- Reduces pain perception by 50–70% in many patients.
- Provides significant relief for conditions like CRPS and neuropathic pain.

Reduced Dependence on Medication:

- Decreases the need for opioids and other analgesics, reducing side effects and addiction risks.

Minimally Invasive:

- A safe alternative to invasive surgeries.
- Minimal downtime and faster recovery.

Reversible:

- The device can be removed if it's ineffective or causes complications.

Improved Quality of Life:

- Patients experience better mobility, sleep, and overall well-being [6,15-19].

Challenges and Limitations

Not Effective for Everyone:

- Some patients may not achieve adequate pain relief.
- Success depends on proper patient selection and device programming.

Cost:

- The high cost of the device and procedure may limit accessibility.

Technical Issues:

- Lead migration or device malfunction can occur, requiring reprogramming or revision surgery.

Adverse Effects:

- Minor risks include infection, bleeding, or nerve damage during implantation.

Discomfort:

- Some patients find the trial period uncomfortable or invasive [2,3,20].

Recent Advances in Spinal Cord Stimulation

Closed-Loop Feedback Systems:

- Real-time monitoring of nerve responses ensures optimal stimulation.
- Eliminates the need for frequent manual adjustments by patients.

MRI-Compatible Devices:

- New devices are compatible with MRI scans, addressing a significant limitation for earlier models.

Wireless and Rechargeable Devices:

- Offer greater convenience and reduce the need for frequent surgical battery replacements.

Targeted Stimulation:

- Advances allow precise targeting of specific pain regions for improved efficacy.

AI-Driven Customization:

- Artificial intelligence is being integrated to tailor stimulation settings based on individual needs [2,17,20-24].

Why Increased Interest in The Modality?

- Improvements in Device Design and Surgical Techniques: Smaller, more compact devices improve patient comfort and reduce complications. Enhanced methods have made implantation less invasive, leading to fewer postoperative issues and lower rates of device explantation.
- Innovative Waveforms: Early SCS systems employed paresthesia-based low-frequency stimulation, leveraging the gate control theory to block pain signals. Modern devices now use advanced waveforms for better outcomes: High-Frequency 10 kHz (HF10) eliminates paresthesia while offering effective pain relief. Burst Stimulation mimics natural brain wave patterns, reducing pain and addressing the emotional aspects of pain. Pulsed Stimulation Patterns (PSP) optimizes energy delivery for targeted pain modulation. Differential Target Multiplex (DTM) focuses on glial cell modulation to enhance therapeutic effects. Closed-Loop Stimulation with Evoked Compound Action Potential (ECAP) allows real-time feedback and precise adjustment of stimulation based on patient variables. [4,23,24]
- Real-Time Feedback and Personalization: Modern SCS systems incorporate real-time monitoring, enabling the device to adjust stimulation based on factors like:

1. Impedance levels.
2. Posture and anatomy (e.g., scar tissue or implanted hardware).
3. Patient position [17,20,23].

- Other Technological Innovations include Battery-Free Devices which improve convenience and reduce the need for surgical replacement. Remote and External Access Devices allow patients and physicians to adjust settings easily. Upgradable Microchips ensure devices stay up-to-date with the latest programming advancements [17,20].

Clinical Evidence Supporting SCS Efficacy in Pain Management

Numerous high-quality clinical studies have established SCS as a safe and effective treatment for refractory chronic pain. Research highlights include long-term pain relief, improved function, and enhanced quality of life; reduced reliance on opioids and associated side effects; cost-effectiveness compared to conservative pain management approaches [1,25].

Indications with Proven Benefits

Conditions where SCS demonstrates significant benefits include persistent spine pain syndrome (PSPS), chronic neuropathic limb pain, complex regional pain syndrome (CRPS) and painful diabetic neuropathy (PDN) [1,2,5,25].

Timing and Healthcare Utilization

Studies show that delaying SCS implantation after the onset of pain increases healthcare costs and resource utilization. Early intervention with SCS may improve outcomes and reduce overall healthcare burdens. SCS reduces long-term healthcare costs by minimizing hospital visits, medication expenses, and lost productivity.

Effectiveness: Studies show that SCS significantly reduces pain intensity in chronic pain patients. It also improves functional outcomes, such as mobility and sleep. A majority of patients report high satisfaction with SCS, citing reduced medication use and improved quality of life [5,7,25].

Expanding Indications for SCS

The field of neuromodulation, particularly SCS, has significantly expanded its scope. Initially limited to a few conditions, SCS now addresses a broader range of pain syndromes, including persistent spine pain syndrome (PSPS), previously known as failed back surgery syndrome (FBSS); complex regional pain syndrome (CRPS);refractory axial neck and lower back pain; neuropathic limb pain and painful diabetic neuropathy (PDN). The use of SCS in these conditions demonstrates its versatility and effectiveness in managing various chronic pain syndromes [18,20,26-29].

Challenges in Adoption

Despite its benefits, SCS is not without challenges which include high device and procedural costs that can limit accessibility, limited indications requiring careful selection of patients, technical complications like lead migration or device malfunctions requiring surgical revisions and MRI compatibility can restrict use in certain patients [17,25,28,29].

Future Directions in SCS

- **Expanded Indications:** On-going research explores new applications for SCS, including migraines, pelvic pain, and cancer pain.
- **Integration with Digital Health:** Devices capable of syncing with mobile apps allow better monitoring and control.
- **Combination Therapies:** SCS combined with cognitive-behavioural therapy, physical therapy, or other modalities may enhance outcomes.
- **Advanced Neural Targeting:** Glial cell modulation and multiplexed waveforms are being studied for their potential to provide precise pain relief.
- **Real-Time Personalization:** Closed-loop systems with real-time feedback offer tailored pain modulation based on individual patient needs [1,17,25,27,29-31].



Figure 5: Acute pain path.



Figure 6: Steps:
Potentiation by repeated NKIR stimulation
Increased NKIR<NMDAR<AMPAR
Post synaptic receptor density upreulated
Paradoxical GABAR depolarization
Lowered electrochemical radiant
Abeta axon spouts
Substance P release increased

- **Mechanisms of Hyperalgesia and Allodynia**

Under normal circumstances, nociception—the process by which pain signals are relayed—operates in a regulated manner. Pain signals from C-fibers (responsible for dull, aching pain) and Aβ fibers (associated with touch) are processed through interneurons before being transmitted via projection neurons to higher centers in the brain. This balanced system ensures that only significant or harmful stimuli elicit pain responses.

However, in cases of nerve injury or repeated stimulation of C-fibers, the nervous system undergoes central sensitization, leading to pathological pain responses like hyperalgesia (increased pain from a normally painful stimulus) and allodynia (pain from a normally non-painful stimulus).

- **Hyperalgesia Arises from Multiple Changes at the Molecular and Cellular Levels:**

1. **Central Sensitization:** Repeated or intense stimulation of peripheral C-fibers causes prolonged excitability in the central nervous system.
2. **Receptor Kinetics and Membrane Potential:** Changes in receptor activity and the resting membrane potential lower the threshold for activating pain signals.
3. **Long-Term Potentiation (LTP):** Enhanced synaptic strength through altered receptor expression, particularly at the postsynaptic density zone, makes neurons more responsive to subthreshold stimuli. This results in exaggerated pain perception.
4. **Neurotransmitters and Receptors:** Molecules like glutamate (Glu), substance P (SP), and calcitonin gene-related peptide (CGRP) interact with receptors such as NMDA, AMPA, and NK1, amplifying pain signals.

- **Allodynia is associated with Changes in the Behaviour of Aβ Fibers, Which Normally Respond to Light Touch but Begin to Signal Pain after Nerve Injury. Key Mechanisms Include:**

1. **Phenotypic Transformation:** Aβ fibers acquire characteristics of pain-transmitting C-fibers, contributing to inappropriate pain signaling.
2. **Axon Sprouting:** After nerve injury, Aβ fibers sprout and form new connections, increasing their interaction with pain pathways.
3. **Substance P Secretion:** Aβ fibers begin releasing SP, a molecule typically associated with pain transmission, further sensitizing the pain pathway.

- **Summary of Molecular Players**

1. **Neurotransmitters:** Glutamate, substance P, glycine (Gly), and gamma-aminobutyric acid (GABA).
2. **Receptors:** NMDA, AMPA, metabotropic glutamate receptor (MGLUR), CGRP receptor, GABA receptor (GABAR), and neurokinin-1 receptor (NK1R).
3. **Neurotrophic Factors:** Brain-derived neurotrophic factor (BDNF) contributes to central sensitization and receptor plasticity.

Together, these changes create a state where the nervous system overreacts to stimuli, leading to heightened pain (hyperalgesia) or pain from non-painful stimuli (allodynia). This is crucial for developing targeted treatments to manage these pathological pain conditions [20].

Conclusion

Spinal Cord Stimulation has transformed pain management by providing a non-invasive, effective solution for chronic pain. With expanding indications, innovative waveforms, and real-time personalization, SCS has become a critical tool for addressing some of the most challenging pain conditions. While challenges like cost and patient selection remain, on-going research and technological improvements promise a brighter future for this transformative therapy. With advancements in technology, its efficacy and accessibility continue to improve, offering hope to millions of patients. The integration of AI, targeted therapies and personalized medicine ensures a promising future for SCS in pain management.

By addressing barriers like cost and patient awareness these modalities can become a cornerstone in the fight against chronic pain, empowering individuals to regain control of their lives. By embracing these advancements, healthcare providers can ensure better outcomes for patients, reducing the burden of chronic pain while improving their quality of life.Collaboration among healthcare professionals and policymakers is essential to address these barriers and improve pain management outcomes.

Financial support and sponsorship: Nil.

Conflict of Interest: None Declared.

References

4. Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, et al. (2018) Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep 67(36): 1001-1006.

5. Fishman MA, Antony A, Esposito M, Deer T, Levy R (2019) The evolution of neuromodulation in the treatment of chronic pain: forward looking perspectives. Pain Med 20(S1): S58-S68.

6. Francio VT, Polston KF, Murphy MT, Hagedorn JM, Sayed D (2021) Management of chronic and neuropathic pain with 10 khz spinal cord stimulation technology: summary of findings from preclinical and clinical studies. Biomedicines 9(6): 644.

7. Heijmans L, Joosten EA (2020) Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic

pain. Postgrad Med 132(S3): 17-21.

8. Deer TR, Levy RM, Kramer J, Poree L, Amirdelfan K, et al. (2017) Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain 158(4): 669-681.
9. Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150(3699): 971-979.
10. Deer TR, Naidu R, Strand N, Sparks D, Abd-Elsayed A, et al. (2020) A review of the bioelectronic implications of stimulation of the peripheral nervous system for chronic pain conditions. Bioelectron Med 6: 9.
11. Claus CF, Lytle E, Kaufmann A, Tong D, Bahoura M, et al. (2020) Minimally invasive sacroiliac joint fusion using triangular titanium versus cylindrical threaded implants: a comparison of patient-reported outcomes. World Neurosurg 133: e745-e750.
12. Rajpal S, Burneikiene S (2019) Minimally invasive sacroiliac joint fusion with cylindrical threaded implants using intraoperative stereotactic navigation. World Neurosurg 122: e1588-e1591.
13. Elbogen EB, Alsobrooks A, Battles S, Molloy K, Dennis PA, et al. (2021) Mobile neurofeedback for pain management in veterans with TBI and PTSD. Pain Med 22(2): 329-337.
14. Lalani J, Rathi M, Lalan M, Misra A. (2013) Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Dev Ind Pharm 39(6): 854-864.
15. Prijic S, Sersa G (2011) Magnetic nanoparticles as targeted delivery systems in oncology. Radiol Oncol 45(1): 1-16.
16. Shealy CN, Mortimer JT, Reswick JB (1967) Electrical inhibition of pain by stimulation of the dorsal columns: preliminary clinical report. Anesth Analg 46(4): 489-491.
17. Arle JE, Mei L, Carlson KW, Shils JL (2016) High-frequency stimulation of dorsal column axons: potential underlying mechanism of paresthesia free neuropathic pain relief. Neuromodulation 19(4): 385-397.
18. Ahmed S, Yearwood T, Ridder D, Vanneste S (2018) Burst and high frequency stimulation: underlying mechanism of action. Expert Rev Med Devices 15(1): 61-70.
19. Linderoth B, Foreman RD (2017) Conventional and novel spinal stimulation algorithms: hypothetical mechanisms of action and comments on outcomes. Neuromodulation 20(6): 525-533.
20. Clingan JA, Patel A, Maher DP (2020) Survey of spinal cord stimulation hardware currently available for the treatment of chronic pain in the United States. Front Pain Res 1: 572907.
21. Sato KL, Johanek LM, Sanada LS, Sluka KA (2014) Spinal cord stimulation reduces mechanical hyperalgesia and glial cell activation in animals with neuropathic pain. Anesth Analg 118(2): 464-472.
22. Thomson S, Huygen F, Prangnell S, Andres J, Baranidharan G, et al. (2020) Appropriate referral and selection of patients with chronic pain for spinal cord stimulation: European consensus recommendations and e-health tool. European Journal of Pain 24(6): 1169-1181.
23. Caylor J, Reddy R, Yin S, Cui C, Huang M, et al. (2019) Spinal cord stimulation in chronic pain: evidence and theory for mechanisms of action. Bioelectron Med 5.
24. Ridder D, Vancamp T, Falowski SM, Vanneste S (2020) All bursts are equal, but some are more equal (to burst fring): burstDR stimulation versus Boston burst stimulation. Expert Rev Med Devices 17(4): 289-295.
25. Cedeno DL, Smith WJ, Kelley CA, Vallejo R (2020) Spinal cord stimulation using differential target multiplexed programming modulates neural cell-specific transcriptomes in an animal model of neuropathic pain. Mol Pain 16.
26. Parker J, Karantonis D, Single P (2020) Hypothesis for the mechanism of action of ECAP-controlled closed-loop systems for spinal cord stimulation. Health Technol Lett 7(3): 76-80.
27. Crosby ND, Weisshaar CL, Smith JR, Zeeman ME, Goodman- Keiser MD, et al. (2015) Burst and tonic spinal cord stimulation differentially activate GABAergic mechanisms to attenuate pain in a rat model of cervical radiculopathy. IEEE Trans Biomed Eng 62(6): 1604-1613.
28. Ferguson SA, Merryweather A, Thiese MS, Hegmann KT, Lu ML, et al. (2019) Prevalence of low back pain, seeking medical care, and lost time due to low back pain among manual material handling workers in the United States. BMC Musculoskelet Disord 20(1): 243.
29. Metzger CS, Hammond MB, Paz-Solis JF, Newton WJ, Thomson SJ, et al. (2021) A novel fast-acting sub-perception spinal cord stimulation therapy enables rapid onset of analgesia in patients with chronic pain.

Expert Rev Med Devices 18(3): 299-306.

30. Vallejo R, Kelley CA, Gupta A, Smith WJ, Vallejo A, et al. (2020) Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain 16: 1744806920918057.

31. Levy R, Chakravarthy K, Poree L, Deer T, Kapural L, et al. (2020) SCS pulsed stimulation patterns (PSP): multiple mechanisms of action in a single, novel waveform (14040). Neuromodulation: Technology at the Neural Interface 23(3): e147-e148.

32. National Institutes of Health (2011) Pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Executive summary.

33. Institute of Medicine (2011) Relieving pain in America: a blueprint for transforming prevention, care, education, and research. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC): The National Academies Press.

34. Zhang TC, Janik JJ, Grill WM (2014) Modelling effects of spinal cord stimulation on wide-dynamic range dorsal horn neurons: influence of stimulation frequency and GABAergic inhibition. J Neurophysiol 112(3): 552-567.